Agenus Inc. (AGEN)
Last updated: 2026-10-21 19:38:00. Prices reflect the latest regular market data. Stock price data is sourced from Massive.
Summary
Agenus Inc. (AGEN) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $6.42, with a market capitalization of $279.10M and a P/E ratio of 3.16. Over the past 52 weeks, its price has ranged from $2.71 to $10.31. This page covers its latest market performance, valuation, price trends and company information.
Key Market Data
$279.10M | |
$6.43 | |
$1,884.00 | |
$1.38 | |
$6.42 | |
178.55K | |
1.24M | |
3.16 | |
$10.31 | |
$2.71 | |
-- | |
-- |
Agenus Inc. (AGEN) Stock Price Today
Agenus Inc. (AGEN) is currently trading at $6.42 as of 2026-10-21 19:22:00, up 0.02% ($0.00) from the previous close of $6.42
During today's regular trading session, AGEN has traded between $1.38 and $1,884.00, with a trading volume of 178.55K shares. The current price is near the lower end of today's range.
Agenus Inc. (AGEN) 7-Day Stock Price Change
Over the past seven days, Agenus Inc. (AGEN) moved from $7.43 to $6.42, representing a decline of 13.58% ($1.01).
The stock traded between $6.00 and $7.66 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 850.64 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
AGEN 52-Week Price Position
Position in Range: 48.8%
AGEN is currently trading at $6.42, placing it 48.8% of the way from its 52-week low of $2.71 to its 52-week high of $10.31. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
What is Agenus Inc. (AGEN)?
Agenus Inc is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Its primary business is immuno-oncology (I-O), where it advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy. The Company's clinical program includes botensilimab (BOT or AGEN1181), both as a monotherapy and in combination with balstilimab (BAL), alongside a portfolio of other clinical-stage immuno-oncology assets that may be used independently or in combination therapies. The Company operates in the United States, which contributes the majority of its revenue, as well as in other international markets.
Agenus Inc. Information
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 81 |
| Exchange | NASDAQ |
| Company Website |
How to Buy Agenus Inc. (AGEN) Stock on MEXC
Eligible investors can buy real shares of Agenus Inc. (AGEN) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Frequently Asked Questions (FAQ)
1.What is Agenus Inc. (AGEN) stock price today?
2.Is AGEN stock going up or down today?
3.What is AGEN pre-market price?
4.What is AGEN after-hours price?
5.Is AGEN stock trading now?
6.Where does AGEN sit relative to its 52-week high and low?
7.What sector is Agenus Inc. in?
8.What is Agenus Inc.'s market capitalization and where is it listed?
9.How is AGEN valued in terms of P/E ratio and EPS?
10.Does Agenus Inc. pay a dividend?
Explore More US Stocks
Search Stocks
AGEN Stock Calculator
Estimate the value between AGEN shares and USD.
AGEN Shares to USD
1.00 AGEN shares = 6.421 USD
Calculations are estimates based on the latest available price and are for reference only.


